NCT04738487 · Interventional trial
Coformulation of Pembrolizumab/Vibostolimab (MK-7684A) Versus Pembrolizumab (MK-3475) Monotherapy for Programmed Cell Death 1 Ligand 1 (PD-L1) Positive Metastatic Non-Small Cell Lung Cancer (MK-7684A-003, KEYVIBE-003)
Overall registry status Terminated
Phase 3
Conditions Lung Neoplasms, Non-Small-Cell Lung Carcinoma
Delaware Valley sites
- Fox Chase Cancer Center-Hematology/Oncology ( Site 0030) · Philadelphia, PA · Philadelphia County
First posted
Registry updated
Added to the directory